HAT1 and melanoma: Our results showed that 7 out of 11 cases of progressed melanoma samples, from patients previously treated with BRAFi or BRAFi+MEKi, showed lower expression levels of HAT1 protein compared with their respective, matched, pre-treatment samples (Fig. 3a, b; Supplementary Fig. S2 and Supplementary Table 1).